Hormone withdrawal-associated symptoms: Overlooked and under-explored

Gynecological Endocrinology

Volumn 29, Issue 6, 2013, Pages 530-535

  Bitzer, Johannes ^a  

^a UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

Author keywords

Cyclical combined oral contraceptives; Extended cycle; Hormone withdrawal associated symptoms; Hormone free interval; HWaS

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DIENOGEST PLUS ESTRADIOL VALERATE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; HORMONE;

ARTICLE; BLOATING; BREAST TENDERNESS; CONSENSUS; HEADACHE; HORMONE WITHDRAWAL ASSOCIATED SYMPTOM; HUMAN; NAUSEA; PATIENT SATISFACTION; PELVIS PAIN SYNDROME; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; SYMPTOM;

ATTITUDE; CONTRACEPTIVES, ORAL, COMBINED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ESTROGENS; FEMALE; HUMANS; MENSTRUAL CYCLE; MENSTRUATION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84877587436     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.760194     Document Type: Article

References (48)

1. Sulak PJ. Continuous oral contraception: Changing times. Best Pract Res Clin Obstet Gynaecol 2008;22:355-74
2. Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997;89:179-83
3. Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-6
4. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: Comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006;195:1311-9
5. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation. Contraception 1995;51:283-8
6. FDA. Guidance for Industry. Combined Oral Contraceptive Labeling for Healthcare Providers and Patients. Available from: Http:// www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm075075.pdf [last accessed 20 May 2011].
7. Grimes DA, Schulz KF. Nonspecific side effects of oral contraceptives: Nocebo or noise? Contraception 2011;83:5-9
8. O'Connell K, Davis AR, Kerns J. Oral contraceptives: Side effects and depression in adolescent girls. Contraception 2007;75:299-304
9. Nappi RE, Nappi G. Neuroendocrine aspects of migraine in women. Gynecol Endocrinol 2012;28:37-41
10. Allais G, Gabellari IC, Airola G, et al. Headache induced by the use of combined oral contraceptives. Neurol Sci 2009;30:S15-7
11. Allais G, Gabellari IC, de Lorenzo C, et al. Oral contraceptives in migraine therapy. Neurol Sci 2011;32:S135-9
12. MacGregor EA, Chia H, Vohrah RC, Wilkinson M. Migraine and menstruation: A pilot study. Cephalalgia 1990;10:305-10
13. MacGregor A. Migraine associated with menstruation. Funct Neurol 2000;15:143-53
14. Johannes CB, Linet MS, Stewart WF, et al. Relationship of headache to phase of the menstrual cycle among young women: A daily diary study. Neurology 1995;45:1076-82
15. Loder EW, Buse DC, Golub Jr. Headache and combination estrogen-progestin oral contraceptives: Integrating evidence, guidelines, and clinical practice. Headache 2005;45:224-31
16. MacGregor EA, Frith A, Ellis J, et al. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 2006;67:2154-8
17. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24:9-160
18. Vaughan B, Trussell J, Kost K, et al. Discontinuation and resumption of contraceptive use: Results from the 2002 National Survey of Family Growth. Contraception 2008;78:271-83
19. Sulak PJ, Kaunitz AM, London AM, et al. Extended regimen oral contraceptives -practical management. OBG Management 2007;56:S1-8
20. Killick SR, Fitzgerald C, Davis A. Ovarian activity in women taking an oral contraceptive containing 20 microg ethinyl estradiol and 150 microg desogestrel: Effects of low estrogen doses during the hormone-free interval. Am J Obstet Gynecol 1998;179:S18-24
21. Mishell Jr. DR. Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations. Contraception 2005;71:304-5
22. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002;186:1142-9
23. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008;78:16-25
24. Guilbert E, Boroditsky R, Black A, et al. Canadian Consensus Guideline on Continuous and Extended Hormonal Contraception, 2007. J Obstet Gynaecol Can 2007;29:S1-32
25. Coffee AL, Sulak PJ, Kuehl TJ. Long-Term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007;75:444-9
26. LaGuardia KD, Fisher AC, Bainbridge JD, et al. Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertil Steril 2005;83:1875-7
27. Edelman AB, GalloMF, Jensen JT, et al. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception (Review). Cochrane Database Syst Rev 2005;3:CD004695
28. Sulak P, Willis S, Kuehl T, et al. Headaches and oral contraceptives: Impact of eliminating the standard 7-day placebo interval. Headache 2007;47:27-37
29. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996;54:71-7
30. Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3mg drospirenone. Contraception 2004;70:191-8
31. Sulak PJ, Carl J, Gopalakrishnan I, et al. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. Contraception 2004;70:281-7
32. Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: A randomized trial. Contraception 2003;67:9-13
33. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary -ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006;74:100-3
34. De Leo V, Scolaro V, Musacchio MC, et al. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril 2011;96:917-20
35. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception 2007;75:16-22
36. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89-96
37. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006;73:229-34
38. Anderson FD, Gibbons W, Portman D. Long-Term safety of an extended-cycle oral contraceptive (Seasonale): A 2-year multicenter open-label extension trial. Am J Obstet Gynecol 2006;195:92-6
39. Anderson FD, Hait H, Hsiu J, et al. Endometrial microstructure after long-Term use of a 91-day extended-cycle oral contraceptive regimen. Contraception 2005;71:55-9
40. DiLiberti CE, O'Leary CM, Hendy CH, et al. Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen. Contraception 2011;83:55-61
41. ACOG Practice Bulletin No. 73. Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006;107:1453-72
42. Bousser MG, Conard J, Kittner S, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society task force on combined oral contraceptives & hormone replacement therapy. Cephalalgia 2000;20:155-6
43. Wiegratz I, Hommel HH, Zimmermann T, Kuhl H. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 2004;69:37-42
44. Andrist LC, Arias RD, Nucatola D, et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 2004;70:359-63
45. Zeun S, Lu M, Uddin A, et al. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2009;14:221-32
46. Mabey Jr. RG, Parke S, Mellinger U, et al. Hormone withdrawalassociated symptoms: Comparison of estradiol valerate/dienogest versus ethinylestradiol/ norgestimate. Abstract plus poster presentation at the 60th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists; 2012 May 5-9; San Diego, CA.
47. Macìas G, Merki-Feld GS, Parke S, et al. Hormone withdrawalassociated symptoms in women taking combined oral contraceptives: Comparison of estradiol valerate/dienogest versus ethinylestradiol/ levonorgestrel. Abstract plus poster presentation at the 15th World Congress on Gynecological Endocrinology; 2012 March 7-10; Firenze, Italy
48. Read CM. New regimens with combined oral contraceptive pills -moving away from traditional 21/7 cycles. Eur J Contracept Reprod Health Care 2010;15:S32-41